Business
NRx Pharmaceuticals Announces Potent Antibacterial Activity of NRX-101 Against Common, Antibiotic Resistant Urinary Pathogens
NRX-101 demonstrated potent antibacterial effect against antibiotic-resistant pathogens in culture medium and in an artificial urine modelD-cycloserine (DCS),
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"NRX-101 demonstrated potent antibacterial effect against antibiotic-resistant pathogens in culture medium and in an artificial urine modelD-cycloserine (DCS), a key component of NRX-101, was originally developed as an anti-infective in the 1950's but was replaced by antibiotics that have since lost effectiveness against complicated Urinary Tract Infections (cUTI)In an era when 90% of cUTI pathogens demonstrate resistance to standard antibiotics, NRX-101 may prove effective in treating cUTI and preventing urosepsisRADNOR, Pa., Sept. 6, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\", the \"Company\"), a clinical-stage biopharmaceutical company, today announced new data that demonstrate potent in vitro activity of NRX-101 (D-cycloserine + lurasidone) against reference strains of Urinary Tract pathogens known to cause complicated urinary tract infections (cUTIs). D-cycloserine (DCS) was originally developed as an anti-infective in the 1950's but was never labeled for treatment of UTI, because of the prevalent and then-effective use of common antibiotics. In recent years, however, cUTI is increasingly caused by pathogens that are resistant to common antibiotics and are increasingly likely to cause sepsis, a lethal condition. Approximately 17,000 deaths per year in the United States are attributed to genitourinary sepsis.1 The study, commissioned by NRx at Charles River Laboratories, is consistent with previously reported academic studies that demonstrate potency of DCS in antibiotic-resistant strains of urinary pathogens.\n\n \n \n \n \n \n \n\n \n\"These newly-obtained data from an internationally-recognized research organization demonstrate that NRX-101 has a potent level of in-vitro activity against dangerous pathogens, such as Pseudomonas and Acinetobacter. DCS was eclipsed by common antibiotics in the 1950s, partly because of the rarity of such pathogens at the time and the effectiveness of first and second generation antibiotics against the common urinary tract pathogens of the day. DCS additionally had an early history of causing mild hallucinations in some patients, although it remains widely used by the World Health Organization. In the studies conducted by NRx and others with DCS in combination with lurasidone and similar drugs, these CNS side effects have not been observed. At the sa...